GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid?
GSK insider Deborah Waterhouse, currently an SVP running the primary care ops of the US pharma division, has been tapped as the new CEO of Viiv, an ambitious joint venture focused on HIV. A 20-year veteran, Waterhouse is taking the place of Dominique Limet, who departs at the end of March. Viiv has been able to make significant progress in adding new products and growing sales, making it a key part of the GSK organization. It’s partnered with Pfizer on the group.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.